Article
Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection
18 Jun 2014
Abstract excerpt
Monitoring allograft health is an important component of posttransplant therapy. Endomyocardial biopsy is the current gold standard for cardiac allograft monitoring but is an expensive and invasive procedure. Proof of principle of a universal, noninvasive diagnostic method based on high-throughput screening of circulating cell-free donor-derived DNA (cfdDNA) was recently demonstrated in a small retrospective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
